





an Open Access Journal by MDPI

# **Antibody Drug Conjugates: Unlocking the Future of Immunotherapies**

Guest Editors:

# Prof. Dr. Deyarina Gonzalez

Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK

### Prof. Dr. R. Steven Conlan

Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK

Deadline for manuscript submissions:

closed (30 June 2023)

# **Message from the Guest Editors**

Dear Colleagues,

Antibody Drug Conjugates (ADC) are quintessential example of advanced biopharmaceutical therapies. These targeted nanomedicines use the specificity of monoclonal antibodies to guide highly potent cytotoxic payloads to specific target cell. The resulting ADCs have a broader therapeutic window than their potent payloads while sparing healthy cells. Currently there are 12 ADCs approved for the treatment of haematological and solid tumour malignancies.

Despite growing interest in this complex biopharmaceutical modality challenges remain to improve ADC quality, safety, and efficacy.

This Special Issue of Pharmaceutics will focus on recent advances in ADC development from ADC design including identification of new targets, antibody selection, development of new conjugation and linker chemistry technologies, novel payloads and mechanism of action, ADC characterisation platforms, to ADC preclinical characterisation including pharmacokinetics, pharmacodynamics, biodistribution, toxicity and efficacy studies and clinical studies looking at oncology and non-oncology applications.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

## **Message from the Editor-in-Chief**

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## **Contact Us**